HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity

FEBS Letters

Volumn 587, Issue 7, 2013, Pages 880-886

  Ding, Gang ^a   Liu, He Dai ^a   Huang, Qian ^a   Liang, Hong Xiang ^a   Ding, Zhao Han ^a   Liao, Zhi Jun ^a   Huang, Gang ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

HDAC6; Hepatocellular carcinoma; Mdm2; p53

Indexed keywords

CYTOKINE; HISTONE DEACETYLASE 6; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN P53; SMALL INTERFERING RNA;

ARTICLE; BINDING SITE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; UPREGULATION;

BINDING SITES; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; HEP G2 CELLS; HISTONE DEACETYLASES; HUMANS; LIVER NEOPLASMS; NF-KAPPA B; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTIONAL ACTIVATION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84875252514     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.02.001     Document Type: Article

References (35)

1. J.M. Llovet, and J. Bruix Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 2008 1312 1327
2. D.Y. But, C.L. Lai, and M.F. Yuen Natural history of hepatitis-related hepatocellular carcinoma World J. Gastroenterol. 14 2008 1652 1656
3. K.M. Ryan, A.C. Phillips, and K.H. Vousden Regulation and function of the p53 tumor suppressor protein Curr. Opin. Cell Biol. 13 2001 332 337
4. D.P. Lane P53 and human cancers Br. Med. Bull. 50 1994 582 599
5. C.J. Sherr, and J.D. Weber The ARF/p53 pathway Curr. Opin. Genet. Dev. 10 2000 94 99
6. K. Sakaguchi, J.E. Herrera, S. Saito, T. Miki, and M. Bustin DNA damage activates p53 through a phosphorylation-acetylation cascade Genes Dev. 12 1998 2831 2841
7. C.L. Brooks, and W. Gu Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation Curr. Opin. Cell Biol. 15 2003 164 171
8. D. Michael, and M. Oren The p53-Mdm2 module and the ubiquitin system Semin. Cancer Biol. 13 2003 49 58
9. R. Honda, H. Tanaka, and H. Yasuda Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 FEBS Lett. 420 1997 25 27
10. A. Valenzuela-Fernandez, J.R. Cabrero, J.M. Serrador, and F. Sanchez-Madrid HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions Trends Cell Biol. 18 2008 291 297
11. Q. Zheng, and X. Wang Autophagy and the ubiquitin-proteasome system in cardiac dysfunction Panminerva Med. 52 2010 9 25
12. G.I. Aldana-Masangkay, and K.M. Sakamoto The role of HDAC6 in cancer J. Biomed. Biotechnol. 2011 2011 875824
13. G.C. Leonardi, S. Candido, M. Cervello, D. Nicolosi, and F. Raiti The tumor microenvironment in hepatocellular carcinoma (review) Int. J. Oncol. 40 2012 1733 1747
14. D.M. Vigushin, and R.C. Coombes Histone deacetylase inhibitors in cancer treatment Anticancer Drugs 13 2002 1 13
15. S.H. Song, S.W. Han, and Y.J. Bang Epigenetic-based therapies in cancer: progress to date Drugs 71 2011 2391 2403
16. J.E. Shabason, P.J. Tofilon, and K. Camphausen HDAC inhibitors in cancer care Oncology (Williston Park) 24 2010 180 185
17. O. Khan, and N.B. La Thangue HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications Immunol. Cell Biol. 90 2012 85 94
18. H. Lee, A. Herrmann, J.H. Deng, M. Kujawski, and G. Niu Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors Cancer Cell 15 2009 283 293
19. T. Lu, S.S. Sathe, S.M. Swiatkowski, C.V. Hampole, and G.R. Stark Secretion of cytokines and growth factors as a general cause of constitutive NFkappaB activation in cancer Oncogene 23 2004 2138 2145
20. F.R. Greten, L. Eckmann, T.F. Greten, J.M. Park, and Z.W. Li IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer Cell 118 2004 285 296
21. T. Leveillard, P. Gorry, K. Niederreither, and B. Wasylyk MDM2 expression during mouse embryogenesis and the requirement of p53 Mech. Dev. 74 1998 189 193
22. E. Gronroos, A.A. Terentiev, T. Punga, and J. Ericsson YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress Proc. Natl. Acad. Sci. USA 101 2004 12165 12170
23. G. Sui, B. Affar el, Y. Shi, C. Brignone, and N.R. Wall Yin Yang 1 is a negative regulator of p53 Cell 117 2004 859 872
24. J.L. Hsieh, C.L. Wu, C.H. Lee, and A.L. Shiau Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function Clin. Cancer Res. 9 2003 338 345
25. B. Bressac, K.M. Galvin, T.J. Liang, K.J. Isselbacher, and J.R. Wands Abnormal structure and expression of p53 gene in human hepatocellular carcinoma Proc. Natl. Acad. Sci. USA 87 1990 1973 1977
26. J. Cho-Rok, J. Yoo, Y.J. Jang, S. Kim, and I.S. Chu Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo Hepatology 43 2006 1042 1052
27. Y.Y. Zhang, and L.M. Zhou Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation Biochem. Biophys. Res. Commun. 423 2012 26 31
28. Y.Y. Zhang, and L.M. Zhou Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells Eur. J. Pharmacol. 698 2013 137 144
29. A.J. Levine P53, the cellular gatekeeper for growth and division Cell 88 1997 323 331
30. U.M. Moll, S. Wolff, D. Speidel, and W. Deppert Transcription-independent pro-apoptotic functions of p53 Curr. Opin. Cell Biol. 17 2005 631 636
31. T.H. Hsieh, C.F. Tsai, C.Y. Hsu, P.L. Kuo, and J.N. Lee Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway FASEB J. 26 2012 778 787
32. Q. Zuo, W. Wu, X. Li, L. Zhao, and W. Chen HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin Oncol. Rep. 27 2012 819 824
33. K. Kanno, S. Kanno, H. Nitta, N. Uesugi, and T. Sugai Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells Oncol. Rep. 28 2012 867 873
34. K.H. Jung, J.H. Noh, J.K. Kim, J.W. Eun, and H.J. Bae Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer Hepatology 56 2012 644 657
35. S. Maeda NF-kappaB, JNK, and TLR signaling pathways in hepatocarcinogenesis Gastroenterol. Res. Pract. 2010 2010 367694